Webinars and Sponsored Roundtables — Register Now

Wednesday, September 30, 2026. 1 PM-1:30 PM ET
Roundtable presenters John Longshore, PhD, Head of Scientific Affairs, Global Oncology Diagnostics, AstraZeneca, and Flora Berisha, MS, Executive Director, Global Head of Diagnostic Partnering and Development, Johnson & Johnson Innovative Medicine, and Mark D. Ewalt, MD, Associate Medical Director for Laboratory Operations, Diagnostic Molecular Pathology, Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, and Isabel Preeshagul, DO, MBS, Thoracic Medical Oncologist, Memorial Sloan Kettering Cancer Center

CAP TODAY does not endorse any of the products or services named within. The roundtable is made possible by a special educational grant from Pillar Biosciences.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Thursday, October 1, 2026 1 PM-2 PM ET
This presentation will explore the value of in-house CGP, offer insights into the benefits and drawbacks of incorporation, and provide information about important practical factors when considering in-house implementation of CGP.

Webinar presenter Allison M. Cushman-Vokoun, MD, PhD, FCAP, Medical Director, Molecular Diagnostics and Personalized Medicine Laboratory, Director, Division of Diagnostic Molecular Pathology and Human Genetics, Henry F. Krous Professor of Pathology, University of Nebraska Medical Center

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Illumina.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Tuesday, October 20, 2026 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.

Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology, Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Roche.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Tuesday, November 3, 2026 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.

Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Subspecialties

Interactive Product Guides

Microbiology


Eyes on new tick-borne disease diagnostics

August 2026—In a summer of more ticks, more diseases, and more tick species expanding to new areas and bringing diseases with them, what Bobbi Pritt, MD, MSc, would like to see are more—and better—diagnostics in early Lyme disease. Laboratory scientists are inching toward improved solutions, though nothing is commercially available now. “I’m cautiously optimistic. I wouldn’t say I’m excited yet,” says Dr. Pritt, co-director of vector-borne diseases laboratory services and chair of the Division of Clinical Microbiology at Mayo Clinic in Rochester.

New susceptibility subsection with a broad scope

April 2026—A new general susceptibility subsection in the microbiology checklist consolidates requirements for antibacterials, antifungals, and antimycobacterials, aiming for clarity and a broader focus beyond bacteriology.

Point-of-care HCV RNA testing: at what cost?

March 2026—A University of Washington study analyzed HCV testing costs across its system from 2017 to 2024, focusing on the public county hospital ED where one-third of diagnoses occur.

More gonorrhea resistance testing needed

April 2025—For Neisseria gonorrhoeae, the pipeline of antibiotics is running dry, and antimicrobial resistance is a global threat. “It’s just a matter of when it’s going to happen,” says Olusegun O. Soge, PhD, MSc, associate professor of global health and of medicine and adjunct associate professor of laboratory medicine and pathology at the University of Washington.

Requirement changes in microbiology, transfusion checklists

February 2025—Some of the CAP accreditation program requirements in the 2024 microbiology and transfusion medicine checklists, in the edition released Dec. 26, have been revised to simplify, clarify, and conserve resources. In transfusion, one new requirement was added to define policy requirements for the use of low-titer group O whole blood.

Respiratory virus readiness, H5N1 ramp-up

November 2024—When it comes to what diseases are predicted to circulate and when, expect a respiratory virus season much like last year’s, and the year before that. As for the severity? “That’s anybody’s guess,” says Alesia McKeown, PhD, scientific partner, medical and scientific affairs at Roche Diagnostics, speaking in late September.

Picture of clinical metagenomic NGS comes into view

August 2024—The number of laboratories performing clinical metagenomic next-generation sequencing is limited, as is the number of sample types for which it’s available, but the range of pathogens mNGS detects is wide open.